Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
STOCKHOLM – August 5, 2019. Karolinska Development's portfolio company Aprea Therapeutics today announced the appointment of Scott Coiante as Senior Vice President and Chief Financial Officer. An...
-
STOCKHOLM – August 5, 2019. Karolinska Development's portfolio company Aprea Therapeutics today announced the appointment of Scott Coiante as Senior Vice President and Chief Financial Officer. An...
-
STOCKHOLM, SVERIGE – 2 augusti 2019. Den 29 maj 2019 offentliggjorde Karolinska Development AB (publ) (”Karolinska Development” eller ”Bolaget”) att styrelsen för Bolaget hade beslutat, under...
-
STOCKHOLM, SWEDEN – 2 August 2019. On 29 May 2019 Karolinska Development AB (Nasdaq Stockholm: KDEV) (“Karolinska Development” or the “Company”) announced that the Board of Directors of the Company...
-
STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has...
-
STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has...
-
STOCKHOLM, SVERIGE – 19 juli 2019. Den 29 maj 2019 offentliggjorde Karolinska Development AB (publ) (”Karolinska Development” eller ”Bolaget”) att styrelsen för Bolaget hade beslutat, under...
-
STOCKHOLM, SWEDEN – 19 July 2019. On 29 May 2019 Karolinska Development AB (Nasdaq Stockholm: KDEV) (“Karolinska Development” or the “Company”) announced that the Board of Directors of the Company...
-
STOCKHOLM – July 9, 2019. Karolinska Development’s portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has enrolled the first...
-
STOCKHOLM – July 9, 2019. Karolinska Development’s portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has enrolled the first...